AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24310737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 15
Study 24310737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 20495102 — intervention group
Group type: EXPERIMENTAL
Intervention: Project ALERT intervention
Number of subjects: 34
Study 18636790 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg/wk for 48 weeks
Number of subjects: 686
Study 18636790 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 686
Study 15983125 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue exercise
Number of subjects: 20
Study 12610022 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan and conventional antihypertensive therapy (CT)
Number of subjects: 0
Study 12610022 — intervention group
Group type: COMPARATOR
Intervention: Placebo and conventional antihypertensive therapy (CT)
Number of subjects: 0
Study 10507209 — intervention group
Group type: EXPERIMENTAL
Intervention: One-Step (OS, Bisco)
Number of subjects: 0
Study 10507209 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond (SB, 3M)
Number of subjects: 0
Study 10507209 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond II (LBII, Kuraray)
Number of subjects: 0
Study 10507209 — intervention group
Group type: EXPERIMENTAL
Intervention: Tokuso Mac Bond II (MBII, Tokuso)
Number of subjects: 0
Study 10507209 — intervention group
Group type: COMPARATOR
Intervention: Ground enamel surfaces (control group)
Number of subjects: 0
Study 7815233 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (Exosurf Neonatal)
Number of subjects: 419
Study 7815233 — intervention group
Group type: COMPARATOR
Intervention: Air placebo
Number of subjects: 419
Study 7815233 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant
Number of subjects: 419
Study 1952132 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 97
Study 1952132 — intervention group
Group type: COMPARATOR
Intervention: saline solution (control)
Number of subjects: 97
Study 7034642 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin plus clavulanic acid
Number of subjects: 22
Study 7034642 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin only
Number of subjects: 22
Study 31330465 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use screening (n=14)
Number of subjects: 29
Study 31330465 — intervention group
Group type: COMPARATOR
Intervention: Physical activity questionnaire (n=15)
Number of subjects: 29
Study 28384735 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin (Centrum Silver)
Number of subjects: 13616
Study 28384735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13616
Study 28384735 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin
Number of subjects: 13616
Study 25918454 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/Hydrochlorothiazide
Number of subjects: 153
Study 25918454 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine/Benazepril
Number of subjects: 153
Study 23416438 — intervention group
Group type: EXPERIMENTAL
Intervention: Gracilis muscle transfer neurotized to cross-facial nerve graft (group I, n=20)
Number of subjects: 47
Study 23416438 — intervention group
Group type: COMPARATOR
Intervention: Gracilis muscle transfer neurotized to ipsilateral masseteric nerve (group II, n=27)
Number of subjects: 47
Study 21836044 — intervention group
Group type: COMPARATOR
Intervention: Endurance exercise (E)
Number of subjects: 10
Study 21836044 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise followed by resistance exercise (ER)
Number of subjects: 10
Study 18823361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of acetylsalicylic acid + paracetamol + caffeine
Number of subjects: 1734
Study 18823361 — intervention group
Group type: COMPARATOR
Intervention: Combination without caffeine
Number of subjects: 1734
Study 18823361 — intervention group
Group type: COMPARATOR
Intervention: Single preparations
Number of subjects: 1734
Study 18823361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1734
Study 17826421 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of antenatal corticosteroids (R-ACS)
Number of subjects: 194
Study 17826421 — intervention group
Group type: COMPARATOR
Intervention: Single course of antenatal corticosteroids followed by placebo (S-ACS)
Number of subjects: 194
Study 14713401 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine therapy
Number of subjects: 0
Study 14713401 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10968496 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,200 microg budesonide daily for 8 weeks
Number of subjects: 61
Study 10968496 — intervention group
Group type: COMPARATOR
Intervention: 1,600 microg budesonide daily for 8 weeks
Number of subjects: 61
Study 9280188 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (3.6 g/d)
Number of subjects: 234
Study 9280188 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (3.8 g/d)
Number of subjects: 234
Study 9280188 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (4.0 g/d, placebo)
Number of subjects: 234
Study 8315953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA) 5 mg/kg/day for adults, 6 mg/kg/day for children for six months, then tapered off by 25% every two months until complete discontinuation.
Number of subjects: 45
Study 8315953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (CsA)
Number of subjects: 45
Study 8315953 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy (control)
Number of subjects: 45
Study 3720391 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal gastric tube airway (EGTA)
Number of subjects: 175
Study 3720391 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal tube (ET)
Number of subjects: 175
Study 30580729 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting of extracranial lesion during thrombectomy
Number of subjects: 984
Study 30580729 — intervention group
Group type: COMPARATOR
Intervention: No stenting of extracranial lesion during thrombectomy
Number of subjects: 984
Study 30514992 — intervention group
Group type: EXPERIMENTAL
Intervention: Motion therapy procedure
Number of subjects: 200
Study 30514992 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motion therapy)
Number of subjects: 200
Study 27429618 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy in addition to conventional periodontal therapy
Number of subjects: 40
Study 27429618 — intervention group
Group type: COMPARATOR
Intervention: Conventional periodontal therapy
Number of subjects: 40
Study 24509967 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 3.75%
Number of subjects: 479
Study 24509967 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 2.5%
Number of subjects: 479
Study 24509967 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 479
Study 23011614 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic ultrasound guidance
Number of subjects: 115
Study 23011614 — intervention group
Group type: EXPERIMENTAL
Intervention: Static ultrasound guidance
Number of subjects: 115
Study 23011614 — intervention group
Group type: COMPARATOR
Intervention: Landmark technique
Number of subjects: 115
Study 20478845 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0
Study 20478845 — intervention group
Group type: COMPARATOR
Intervention: Rest
Number of subjects: 0
Study 18280326 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate transfer for PCI
Number of subjects: 600
Study 18280326 — intervention group
Group type: COMPARATOR
Intervention: Standard care/rescue PCI
Number of subjects: 600
Study 15714113 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate DAS group (n = 10)
Number of subjects: 30
Study 15714113 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow DAS group (n = 10)
Number of subjects: 30
Study 15714113 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 30
Study 12784108 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (transdermal administration over 3 days)
Number of subjects: 12
Study 12784108 — intervention group
Group type: COMPARATOR
Intervention: Testosterone (transdermal administration over 3 days)
Number of subjects: 12
Study 10647762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (tinzaparin sodium) given once daily
Number of subjects: 200
Study 10647762 — intervention group
Group type: COMPARATOR
Intervention: Intravenous heparin (dose-adjusted)
Number of subjects: 200
Study 10647762 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (tinzaparin sodium)
Number of subjects: 200
Study 9035508 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone for 8 weeks
Number of subjects: 96
Study 9035508 — intervention group
Group type: COMPARATOR
Intervention: Prednisone for 12 weeks
Number of subjects: 96
Study 1391257 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshly frozen plasma infusion (FFP) 10 ml/kg on days 1-3
Number of subjects: 35
Study 1391257 — intervention group
Group type: COMPARATOR
Intervention: No FFP
Number of subjects: 35
Study 4002789 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine
Number of subjects: 6
Study 4002789 — intervention group
Group type: EXPERIMENTAL
Intervention: muzolimine with Aludrox
Number of subjects: 6
Study 4002789 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 28608744 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 63
Study 28608744 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 31027191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of vitamin D and aerobic training (DAT)
Number of subjects: 0
Study 31027191 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (D)
Number of subjects: 0
Study 31027191 — intervention group
Group type: COMPARATOR
Intervention: Aerobic training (AT)
Number of subjects: 0
Study 31027191 — intervention group
Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 0
Study 27845337 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis 35624 (109 c.f.u. per day)
Number of subjects: 302
Study 27845337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 302
Study 25406436 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Online Weight Reduction (POWeR) programme with brief human support
Number of subjects: 0
Study 25406436 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Online Weight Reduction (POWeR) programme with regular human support
Number of subjects: 0
Study 25406436 — intervention group
Group type: COMPARATOR
Intervention: Positive Online Weight Reduction (POWeR) programme
Number of subjects: 0
Study 24079645 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 20
Study 24079645 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mitiglinide and voglibose (1 tablet 3 times daily)
Number of subjects: 20
Study 21640574 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 81
Study 21640574 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg
Number of subjects: 81
Study 19656087 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban with rescue PCI
Number of subjects: 112
Study 19656087 — intervention group
Group type: COMPARATOR
Intervention: Rescue PCI without tirofiban
Number of subjects: 112
Study 16824852 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE 0.625 mg/d)
Number of subjects: 10739
Study 15326131 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure phosphene tonometer (PPT)
Number of subjects: 102
Study 15326131 — intervention group
Group type: COMPARATOR
Intervention: Goldmann tonometer (GT)
Number of subjects: 102
Study 11290865 — intervention group
Group type: EXPERIMENTAL
Intervention: R115777 200 mg/dose, escalated to 300 mg b.i.d. for 28 days
Number of subjects: 9
Study 11290865 — intervention group
Group type: EXPERIMENTAL
Intervention: R115777 300 mg b.i.d. for 28 days
Number of subjects: 9
Study 11290865 — intervention group
Group type: EXPERIMENTAL
Intervention: R115777 pharmacokinetics
Number of subjects: 9
Study 9706365 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recruitment (contacting targeted individuals in person, by phone, or by mail)
Number of subjects: 126
Study 9706365 — intervention group
Group type: COMPARATOR
Intervention: Passive recruitment (informing the community through public notices and waiting for volunteers to call)
Number of subjects: 126
Study 9706365 — intervention group
Group type: COMPARATOR
Intervention: Passive recruitment
Number of subjects: 126
Study 7523788 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 20
Study 7523788 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20
Study 3066417 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral tablet of lorazepam
Number of subjects: 12
Study 3066417 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg sublingual tablet of lorazepam
Number of subjects: 12
Study 3066417 — intervention group
Group type: COMPARATOR
Intervention: Oral lorazepam
Number of subjects: 12
Study 3066417 — intervention group
Group type: COMPARATOR
Intervention: Sublingual lorazepam
Number of subjects: 12
Study 2250886 — intervention group
Group type: EXPERIMENTAL
Intervention: Lid scrubs and massage for MGD treatment
Number of subjects: 21
Study 2250886 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no treatment)
Number of subjects: 21
Study 2250886 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective comfort with contact lens wear after therapy
Number of subjects: 21
Study 4202264 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies
Number of subjects: 0
Study 4202264 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate
Number of subjects: 0
Study 4202264 — intervention group
Group type: EXPERIMENTAL
Intervention: IgE estimation
Number of subjects: 0
Study 31384885 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) testing intervention
Number of subjects: 0
Study 31384885 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation modelling based on data from the European Randomized study of Screening for Prostate Cancer
Number of subjects: 0
Study 31384885 — intervention group
Group type: COMPARATOR
Intervention: C-recommendation on screening for prostate cancer
Number of subjects: 0
Study 27815511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg once daily (QD)
Number of subjects: 603
Study 27815511 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg twice daily (BID)
Number of subjects: 603
Study 27815511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603
Study 25837219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity score (DDS) quartiles
Number of subjects: 397
Study 23523692 — intervention group
Group type: EXPERIMENTAL
Intervention: MK‐0249 10mg
Number of subjects: 55
Study 23523692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 21256805 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimavanserin (1, 2.5, 5, or 20 mg)
Number of subjects: 45
Study 21256805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 18832532 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based formula
Number of subjects: 159
Study 18832532 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed cow's milk protein (CMP), low-lactose formula (PHF)
Number of subjects: 159
Study 16247575 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case TEP
Number of subjects: 200
Study 16247575 — intervention group
Group type: COMPARATOR
Intervention: Open Lichtenstein hernioplasty
Number of subjects: 200
Study 15322036 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD/T11 coadministered with DTwP/IPV/PRP-T (whole-cell pertussis)
Number of subjects: 0
Study 15322036 — intervention group
Group type: EXPERIMENTAL
Intervention: PncD/T11 coadministered with DTaP/IPV/PRP-T (acellular pertussis)
Number of subjects: 0
Study 11483802 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with AA+DHA (egg-DTG)
Number of subjects: 239
Study 11483802 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with AA+DHA (fish/fungal)
Number of subjects: 239
Study 11483802 — intervention group
Group type: COMPARATOR
Intervention: Control formula (no AA or DHA)
Number of subjects: 239
Study 11483802 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants (reference group)
Number of subjects: 239
Study 11483802 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 239
Study 9753527 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (100 mg daily)
Number of subjects: 34
Study 9753527 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (1 mg daily)
Number of subjects: 34
Study 9753527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 7820218 — intervention group
Group type: EXPERIMENTAL
Intervention: New onset IDDM
Number of subjects: 20
Study 7820218 — intervention group
Group type: COMPARATOR
Intervention: Long-standing IDDM
Number of subjects: 20
Study 7820218 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 3337274 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine skin patch for 48 hours prior to study
Number of subjects: 8
Study 3337274 — intervention group
Group type: COMPARATOR
Intervention: Placebo skin patch for 48 hours prior to study
Number of subjects: 8
Study 29234923 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus TEM
Number of subjects: 173
Study 29234923 — intervention group
Group type: COMPARATOR
Intervention: TME
Number of subjects: 173
Study 25351282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii intervention
Number of subjects: 10
Study 26627879 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 5365
Study 26627879 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin
Number of subjects: 5365
Study 23393067 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 22
Study 23393067 — intervention group
Group type: COMPARATOR
Intervention: CMR
Number of subjects: 22
Study 20964660 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene/betamethasone dipropionate two-compound scalp formulation (n=135)
Number of subjects: 177
Study 20964660 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n=42)
Number of subjects: 177
Study 20964660 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriene/betamethasone dipropionate two-compound scalp formulation
Number of subjects: 177
Study 20964660 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 177
Study 18383960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 microg x kg(‐1)
Number of subjects: 90
Study 18383960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 microg x kg(‐1)
Number of subjects: 90
Study 18383960 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 0.4 microg x kg(‐1)
Number of subjects: 90
Study 16331635 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 courses of dose-escalated CHOP plus etoposide (megaCHOEP)
Number of subjects: 84
Study 16331635 — intervention group
Group type: COMPARATOR
Intervention: 6 courses of dose-escalated CHOP plus etoposide (megaCHOEP)
Number of subjects: 84
Study 14616412 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (200 mg twice daily) + Phenytoin (300 mg once daily)
Number of subjects: 36
Study 14616412 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice daily) + Phenytoin (300 mg once daily)
Number of subjects: 36
Study 14616412 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg once daily) + Voriconazole (400 mg twice daily)
Number of subjects: 36
Study 14616412 — intervention group
Group type: COMPARATOR
Intervention: Voriconazole + Placebo
Number of subjects: 36
Study 14616412 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin + Placebo
Number of subjects: 36
Study 11591255 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI group
Number of subjects: 100
Study 11591255 — intervention group
Group type: COMPARATOR
Intervention: Non-professional hCG administration
Number of subjects: 100
Study 9160930 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study 9160930 — intervention group
Group type: EXPERIMENTAL
Intervention: Other controlled trials
Number of subjects: 0
Study 9160930 — intervention group
Group type: EXPERIMENTAL
Intervention: Other analytical studies
Number of subjects: 0
Study 9160930 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive studies
Number of subjects: 0
Study 9160930 — intervention group
Group type: EXPERIMENTAL
Intervention: True audits
Number of subjects: 0
Study 9160930 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evidence base for otolaryngology
Number of subjects: 0
Study 7934595 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulator
Number of subjects: 113
Study 3251162 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP, 30 micrograms/kg/h)
Number of subjects: 11
Study 3251162 — intervention group
Group type: COMPARATOR
Intervention: Saline (NaCl 150 mmol/1-50 ml/h)
Number of subjects: 11
Study 30444856 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermia (<36°C)
Number of subjects: 680
Study 30444856 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (36‐38.5°C)
Number of subjects: 680
Study 29176714 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 29176714 — intervention group
Group type: COMPARATOR
Intervention: Glipizide
Number of subjects: 0
Study 25036417 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative education and orientation for scoliosis surgery (PEOSS)
Number of subjects: 65
Study 25036417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative education)
Number of subjects: 65
Study 23479253 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze Training (GT)
Number of subjects: 36